This report evaluates the impact of the Guardant360 CDx test (Guardant Health Inc.) as a companion diagnostic on patient survival.
Precision Medicine
The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:
- Will testing change patient management for this indication?
- If so, what tests and/or therapies should I use?
- Should we cover testing and/or therapies?
- Can we manage these services internally?
- Precision Medicine Insights
- Precision Medicine Research Briefs
ExoDx Prostate Test (Exosome Diagnostics Inc.)
This report evaluates the clinical validity and clinical utility of the ExoDx Prostate test (Exosome Diagnostics Inc.).
GeneStrat (Biodesix Inc.)
This report evaluates the clinical validity and clinical utility of the GeneStrat targeted genomic test (Biodesix Inc.).
Cologuard (Exact Sciences Corp.) for Colorectal Cancer Screening in Average-Risk Adults
This report evaluates the clinical validity and clinical utility of the Cologuard test (Exact Sciences Corp.).
ThyroSeq v3 Genomic Classifier (University of Pittsburgh Medical Center and Sonic Healthcare USA)
This report evaluates the clinical validity and clinical utility of the ThyroSeq v3 Genomic Classifier (University of Pittsburgh Medical Center and Sonic Healthcare USA).
Signatera (Natera Inc.)
This report evaluates the clinical validity and clinical utility of the Signatera test.
Prostate Health Index (Beckman Coulter Inc.) for Prebiopsy Triage
This report evaluates the analytical validity, clinical validity, and clinical utility of the Prostate Health Index (phi) (Beckman Coulter Inc.).
Comprehensive Molecular Profiling of Circulating Solid Tumor DNA for the Intended Use as a Broad Molecular Profiling Tool for Monitoring
This report reviews clinical study abstracts and clinical practice guidelines addressing comprehensive molecular profiling (CMP) of circulating solid tumor DNA as a broad molecular profiling tool to aid in monitoring for indicators of treatment response/failure or tumor progression. This report will focus solely on free ctDNA detected in plasma separated from whole blood samp…
Comprehensive Molecular Profiling of Circulating Solid Tumor DNA for the Intended Use as a Broad Molecular Profiling Tool to Aid Treatment Selection
This report reviews clinical study abstracts and clinical practice guidelines addressing comprehensive molecular profiling (CMP) of circulating solid tumor DNA as a broad molecular profiling tool to aid in decision making regarding biomarker-matched treatment selection (including U.S. Food and Drug Administration [FDA]-approved or off-label use). This report will focus solely…
PancraGEN (Interpace Diagnostics)
This report evaluates the analytical validity, clinical validity, and clinical utility of the PancraGEN (Interpace Diagnostics) test.